CO2022012059A2 - Aerosol que comprende 5-metoxi-n,n-dimetiltriptamina - Google Patents

Aerosol que comprende 5-metoxi-n,n-dimetiltriptamina

Info

Publication number
CO2022012059A2
CO2022012059A2 CONC2022/0012059A CO2022012059A CO2022012059A2 CO 2022012059 A2 CO2022012059 A2 CO 2022012059A2 CO 2022012059 A CO2022012059 A CO 2022012059A CO 2022012059 A2 CO2022012059 A2 CO 2022012059A2
Authority
CO
Colombia
Prior art keywords
dimethyltryptamine
methoxy
aerosol containing
aerosols
dmt
Prior art date
Application number
CONC2022/0012059A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of CO2022012059A2 publication Critical patent/CO2022012059A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Abstract

Se proporcionan aerosoles de 5-metoxi-N,N-dimetiltriptamina (5-MeO-DMT) o una sal farmacéuticamente aceptable que son útiles para la administración a un paciente a través de una vía de inhalación. Los aerosoles tienen densidades de masa de partículas de aerosol en el intervalo de aproximadamente 0,5 mg/l a aproximadamente 12,5 mg/l.
CONC2022/0012059A 2020-02-24 2022-08-24 Aerosol que comprende 5-metoxi-n,n-dimetiltriptamina CO2022012059A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159161.7A EP3868364A1 (en) 2020-02-24 2020-02-24 Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
PCT/EP2021/054502 WO2021170614A1 (en) 2020-02-24 2021-02-24 Aerosol comprising 5-methoxy-n.n-dimethyltryptamine

Publications (1)

Publication Number Publication Date
CO2022012059A2 true CO2022012059A2 (es) 2022-11-29

Family

ID=69740131

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012059A CO2022012059A2 (es) 2020-02-24 2022-08-24 Aerosol que comprende 5-metoxi-n,n-dimetiltriptamina

Country Status (15)

Country Link
US (1) US20230075124A1 (es)
EP (2) EP3868364A1 (es)
JP (1) JP2023513954A (es)
KR (1) KR20220164704A (es)
CN (1) CN115427019A (es)
AU (1) AU2021228914A1 (es)
BR (1) BR112022015758A2 (es)
CA (1) CA3172772A1 (es)
CL (1) CL2022002303A1 (es)
CO (1) CO2022012059A2 (es)
CR (1) CR20220417A (es)
IL (1) IL295758A (es)
MX (1) MX2022010417A (es)
PE (1) PE20221577A1 (es)
WO (1) WO2021170614A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023186823A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of cognitive dysfunction
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2002094216A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of stimulants through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
EP4353314A2 (en) 2019-02-22 2024-04-17 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression

Also Published As

Publication number Publication date
PE20221577A1 (es) 2022-10-06
MX2022010417A (es) 2022-09-07
JP2023513954A (ja) 2023-04-04
IL295758A (en) 2022-10-01
US20230075124A1 (en) 2023-03-09
CN115427019A (zh) 2022-12-02
EP4110295A1 (en) 2023-01-04
CR20220417A (es) 2022-10-10
CA3172772A1 (en) 2021-09-02
CL2022002303A1 (es) 2023-01-27
EP3868364A1 (en) 2021-08-25
KR20220164704A (ko) 2022-12-13
AU2021228914A1 (en) 2022-10-13
WO2021170614A1 (en) 2021-09-02
BR112022015758A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
CO2022012059A2 (es) Aerosol que comprende 5-metoxi-n,n-dimetiltriptamina
ES2384384T3 (es) Formulaciones inhalables para tratar la hipertensión pulmonar y procedimientos de uso de las mismas
Jonzon et al. Adenosine receptor mediated inhibition of noradrenaline release from slices of the rat hippocampus
AR092261A1 (es) Composiciones de nicotina
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
CR7654A (es) Una combinacion de azelatina y esteroides
NI201200172A (es) Activadores de guanilato ciclasa soluble
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
AR044383A1 (es) Composiciones farmaceuticas de vareniclina
SV2002000969A (es) Composicion parenteral reconstituible
CN105163749A (zh) 治疗骨髓性白血病的方法
RU2014101261A (ru) Системы, способы и составы для лечения рака
CO2022019131A2 (es) Inhibidores de la quinasa nek7
AR117150A1 (es) Formulaciones farmacéuticas de análogos de ciclosporina
AR036312A1 (es) Composicion farmaceutica
Moulinoux et al. The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation
Yates et al. Effect of imipramine and some analogues on the uptake of 5‐hydroxytryptamine by human blood platelets in vitro
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
ECSP066274A (es) Saquinavir mesilato, forma de dosificacion oral
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
UY28457A1 (es) Nueva composición
AR103719A1 (es) Composición líquida tópica para el lavado intrauterino que contiene melatonina
AR038764A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
AR030364A1 (es) Compuestos para el tratamiento de desordenes adictivos
CO6241136A2 (es) Formulaciones orales de liberacion controlada de compuestos moduladores de canal ionico y metodos relacionados para la prevencion de arritmias